The company that invented gene editing went bankrupt the week the field had its biggest wins

Biotech & Longevity 4 min 80 sources

Sangamo Therapeutics, which coined the term "genome editing" 20 years ago, filed for Chapter 11 — the same week a CRISPR rival posted a landmark trial and a man was cured of sickle cell. The pioneer built the road; the followers are driving it.

Key takeaways

Sangamo, the company that helped invent gene editing 20 years ago, filed for bankruptcy this week — its science is being sold to Lilly and Astellas even as the field it founded is thriving.
The same week, rival Intellia posted a landmark 87% reduction in attacks with a newer CRISPR therapy, and a young man in Louisiana was functionally cured of sickle cell disease with an edited-cell treatment.
A company can have the breakthrough and still run out of money before it pays off — and the firms that arrive later, with better tools, often collect the reward the pioneer paid to make possible.

The strangest thing in biotech this week is a single coincidence of timing. On Wednesday, Sangamo Therapeutics — a Bay Area company that has worked on gene editing for more than 30 years, and whose scientists helped coin the term “genome editing” itself — filed for bankruptcy [13]. In the same seven days, a younger rival posted some of the best gene-editing trial data the field has seen [7], and a 23-year-old in Louisiana was functionally cured of sickle cell disease with an edited-cell therapy [18].

The field is winning. One of its founders is gone. That is the story.

The pioneer that ran out of road

Sangamo was founded in 1995. In 2005, its scientists were the first to edit a precise letter of human DNA in the lab — the experiment that gave “genome editing” its name [13]. Its technology was the first gene-editing platform ever to reach a clinical trial, starting with HIV and moving through a string of rare genetic diseases [13]. For most of two decades it was, by any honest measure, ahead.

It filed for Chapter 11 bankruptcy protection in Delaware on Wednesday [13]. Chapter 11 is the US process where a company that cannot pay its debts reorganises or sells itself off rather than shutting the doors overnight. Sangamo arranged for two large drugmakers — Eli Lilly and Astellas — to act as opening bidders for its assets: its delivery technology and its original zinc-finger editing platform to Lilly, its Fabry disease program to Astellas [13]. The science is being bought. The company is not surviving.

What went wrong was not the science. Sangamo had real data — all 25 patients in an early trial of its Fabry disease therapy held steady, one of them for three years [13]. It won the FDA’s agreement on a faster approval path in 2024, and its shares jumped 69% on the news [13]. But it kept running short of cash. Back in 2023 it had already deferred its big confirmatory trial because it had no partner to fund it, cut 40% of its US staff, and narrowed its pipeline [13]. A company can have the breakthrough and still not have the money to carry it the last mile.

The rival that arrived later — and is soaring

Two months ago and again this week, Intellia Therapeutics posted strong results from a late-stage trial of a CRISPR therapy for hereditary angioedema, a rare condition that causes sudden, dangerous swelling attacks [7]. The therapy cut the average number of monthly attacks by 87% — a single infusion that edits a gene inside the body [7]. Investors took the data as proof the drug merits approval; Intellia’s shares rose 29% in four days and are up more than 76% over six months [7].

CRISPR — the gene-editing tool that won a Nobel Prize in 2020 — is faster, cheaper, and easier to aim than the zinc-finger method Sangamo pioneered [7][13]. Intellia did not invent gene editing. It arrived after the hard, early questions had been answered, picked up the better tool, and is now collecting the reward. The order of events matters: the pioneer spent years and money proving the idea was even possible; the follower built on settled ground.

What an edit can already do

The week’s third story is what all of this is for. Daniel Cressy, 23, of Metairie, Louisiana, became the first person in his state to be functionally cured of sickle cell disease — a painful, inherited blood disorder that mostly affects Black Americans and can shorten lives [18]. Doctors removed his stem cells, edited them to fix the genetic flaw, and returned them; his body now makes healthy blood [18]. “Functionally cured” means the disease no longer attacks his body — an honest term, not a promise that nothing can ever go wrong [18].

Cressy had wanted to fly commercial jets since childhood, but the FAA would not license a pilot with sickle cell [18]. The cure cleared his path. It is one patient, an expensive and intensive procedure, and gene-edited cell therapies remain out of reach for most who could use them [18]. But it is the thing the whole field has been trying to reach for 30 years — and the company that started the chase did not live to see this week’s version of it.

The same week, in money

The bankruptcy lands inside a broader rush. Germany’s Merck agreed to buy lab-tools maker Bio-Techne for about $11 billion [4][11]. AbbVie closed a nearly $11 billion deal for Apogee Therapeutics, a biotech whose lead drug is still unproven [39][66]. The Financial Times noted the wave of buyouts is being driven by more than the usual patent expiries [61]. The pattern is consistent: established companies with cash are buying the science, whether from a thriving startup or a bankrupt pioneer. The work survives by changing owners.

02 · Lesson · why it matters

The one who clears the road rarely gets to drive it

The hardest, most expensive work is proving something is possible at all — and the people who do it are usually not the ones who get rich from it.

A founder dies the week its field wins

Sangamo Therapeutics spent more than thirty years on gene editing. Its scientists ran the experiment that gave “genome editing” its name. Its technology was the first of its kind to reach a human trial. This week it filed for bankruptcy — and in the same seven days, a younger rival posted some of the best gene-editing data the field has ever seen, and a man was cured of a disease Sangamo’s whole industry was built to beat.

It is tempting to read this as Sangamo failing. It is more honest to read it as Sangamo succeeding at the part nobody pays for. Someone had to prove that you could edit a precise letter of human DNA and not break the patient. Someone had to walk into the regulator’s office first, with no map. Sangamo did that work. The reward for doing it went mostly to the companies that came after.

The first mile costs the most

When something has never been done, the cost is not mainly the doing. It is the not knowing whether it can be done at all. The first company into a new kind of medicine spends years and fortunes answering questions that, once answered, are free for everyone else: Is this safe? How do you deliver it? What does the FDA need to see? Each answer is paid for once, in full, by whoever asks it first — and then it sits there, settled, for the next firm to pick up at no charge.

This is why being early is not the same as being ahead. Sangamo had the head start and the real data. What it kept running out of was money — it had already deferred its big trial and cut 40% of its staff years ago, simply because the first mile is so long and so expensive that you can do everything right and still not reach the end with cash in hand.

The follower travels light

Intellia, the rival now soaring, did not invent gene editing. It arrived later, carrying CRISPR — a newer tool that is cheaper, faster, and easier to aim than the method Sangamo pioneered. It built on ground that was already cleared. The basic question of whether you can safely edit a gene inside a living person had been pushed forward, at great cost, by the people who went before. Intellia inherited that and added its own work on top.

That is not cheating. It is how progress moves. The follower is genuinely better — newer tool, sharper aim, real results. But notice what made “better” possible: a road someone else paid to build. The 87% drop in attacks that lifted Intellia’s stock this week sits on twenty years of accumulated, mostly invisible groundwork — much of it done by companies whose names you will never hear, some now bankrupt.

You are standing on roads you didn’t build

Step back from biotech and the pattern is everywhere, including in your own life. The cheap, reliable thing you use without a second thought — a vaccine, a search engine, a way of doing your job — is almost always the late, polished version. The expensive, failed, half-working early versions came first, and the people who built them rarely got the payoff. You inherited the road. You did not pay the toll for clearing it.

This cuts two ways, and both are worth holding. When you benefit from something easy, some of that ease was bought by someone who went first and lost. And when you are the one going first — in a job nobody’s done, a path nobody’s walked — the difficulty you feel is not a sign you’re doing it wrong. It may be the simple cost of being early, the toll that later arrivals will never have to pay.

The whole, seen plainly

A field can be thriving and one of its founders can be dying, in the same week, for reasons that don’t contradict each other at all. The win and the bankruptcy are the same story told from two seats. Sangamo’s science is not vanishing — Lilly and Astellas are buying it, the cures keep coming, the man in Louisiana can fly. The work survives. The company that started it does not.

It is worth sitting with that the next time something looks like a clean success — a stock soaring, a cure announced, a problem solved. Behind the visible winner is usually a longer line of people and firms who paid the price of going first and never appear in the headline. The whole picture includes them. We mostly only see the last one standing.

03 · Lab · your turn

Who Pays To Clear The Road

Choose to pioneer, move early, or follow a new medicine — and feel how the cost of going first lands on the trailblazer while the reward flows to whoever arrives once the road is paved.

04 · Hope · carry this

A company can fall and its discovery still reaches the patient who needed it — proof that progress is a relay, not a race, and that the road we build for each other outlasts any of us who lay a stretch of it.